[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550799":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":36,"centralContacts":41,"locations":50,"responsibleParty":181,"collaborators":35,"id":183,"slug":184,"hasResults":185,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":35,"eligibilityCriteria":189,"healthyVolunteers":185,"sex":190,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":35,"studyType":196,"phases":197,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":53,"whyStopped":35,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},{"fullName":5,"class":6},"Verve Therapeutics, Inc.","INDUSTRY",[8,14,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Single Ascending Dose Escalation","EXPERIMENTAL","Participants will receive a single dose of VERVE-201.",[13],"Drug: VERVE-201",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort 2: Single Ascending Dose Escalation",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort 3: Single Ascending Dose Escalation",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Cohort 4: Single Ascending Dose Escalation",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort 5: Single Ascending Dose Escalation",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Cohort 6: Single Ascending Dose Escalation",[13],[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","VERVE-201","Intravenous (IV) infusion",[9,15,18,21,24,27],null,[37],{"name":38,"affiliation":39,"role":40},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","Eli Lilly and Company","STUDY_DIRECTOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":35,"email":46},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","317-615-4559","LillyTrials@Lilly.com",{"name":48,"role":44,"phone":35,"phoneExt":35,"email":49},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[51,65,73,81,89,98,105,114,121,128,137,146,153,162,169,177],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":35},"Clinical Study Center","RECRUITING","Clearwater","Florida","33756","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-82.8001,27.96585,{"lat":63,"lon":62},{"facility":52,"status":53,"city":66,"state":55,"zip":67,"country":57,"countryCode":58,"cosmosGeoPoint":68,"geoPoint":72,"contacts":35},"Miami Lakes","33016",{"type":60,"coordinates":69},[70,71],-80.30866,25.90871,{"lat":71,"lon":70},{"facility":52,"status":53,"city":74,"state":55,"zip":75,"country":57,"countryCode":58,"cosmosGeoPoint":76,"geoPoint":80,"contacts":35},"Port Orange","32127",{"type":60,"coordinates":77},[78,79],-80.99561,29.13832,{"lat":79,"lon":78},{"facility":52,"status":53,"city":82,"state":82,"zip":83,"country":57,"countryCode":58,"cosmosGeoPoint":84,"geoPoint":88,"contacts":35},"New York","10029",{"type":60,"coordinates":85},[86,87],-74.00597,40.71427,{"lat":87,"lon":86},{"facility":52,"status":53,"city":90,"state":35,"zip":35,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":35},"Adelaide","Australia","AU",{"type":60,"coordinates":94},[95,96],138.59863,-34.92866,{"lat":96,"lon":95},{"facility":52,"status":53,"city":99,"state":35,"zip":35,"country":91,"countryCode":92,"cosmosGeoPoint":100,"geoPoint":104,"contacts":35},"Melbourne",{"type":60,"coordinates":101},[102,103],144.96332,-37.814,{"lat":103,"lon":102},{"facility":52,"status":53,"city":106,"state":35,"zip":35,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":35},"Chicoutimi","Canada","CA",{"type":60,"coordinates":110},[111,112],-71.06369,48.41963,{"lat":112,"lon":111},{"facility":52,"status":53,"city":115,"state":35,"zip":35,"country":107,"countryCode":108,"cosmosGeoPoint":116,"geoPoint":120,"contacts":35},"Montreal",{"type":60,"coordinates":117},[118,119],-73.58781,45.50884,{"lat":119,"lon":118},{"facility":52,"status":53,"city":122,"state":35,"zip":35,"country":107,"countryCode":108,"cosmosGeoPoint":123,"geoPoint":127,"contacts":35},"Toronto",{"type":60,"coordinates":124},[125,126],-79.39864,43.70643,{"lat":126,"lon":125},{"facility":52,"status":53,"city":129,"state":35,"zip":35,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":35},"Amsterdam","Netherlands","NL",{"type":60,"coordinates":133},[134,135],4.88969,52.37403,{"lat":135,"lon":134},{"facility":52,"status":53,"city":138,"state":35,"zip":35,"country":139,"countryCode":140,"cosmosGeoPoint":141,"geoPoint":145,"contacts":35},"Cape Town","South Africa","ZA",{"type":60,"coordinates":142},[143,144],18.42322,-33.92584,{"lat":144,"lon":143},{"facility":52,"status":53,"city":147,"state":35,"zip":35,"country":139,"countryCode":140,"cosmosGeoPoint":148,"geoPoint":152,"contacts":35},"Johannesburg",{"type":60,"coordinates":149},[150,151],28.04363,-26.20227,{"lat":151,"lon":150},{"facility":52,"status":53,"city":154,"state":35,"zip":35,"country":155,"countryCode":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":35},"Liverpool","United Kingdom","UK",{"type":60,"coordinates":158},[159,160],-2.97794,53.41058,{"lat":160,"lon":159},{"facility":52,"status":53,"city":163,"state":35,"zip":35,"country":155,"countryCode":156,"cosmosGeoPoint":164,"geoPoint":168,"contacts":35},"London",{"type":60,"coordinates":165},[166,167],-0.12574,51.50853,{"lat":167,"lon":166},{"facility":170,"status":53,"city":171,"state":35,"zip":35,"country":155,"countryCode":156,"cosmosGeoPoint":172,"geoPoint":176,"contacts":35},"Clinical Study Center 2","Manchester",{"type":60,"coordinates":173},[174,175],-2.23743,53.48095,{"lat":175,"lon":174},{"facility":52,"status":53,"city":171,"state":35,"zip":35,"country":155,"countryCode":156,"cosmosGeoPoint":178,"geoPoint":180,"contacts":35},{"type":60,"coordinates":179},[174,175],{"lat":175,"lon":174},{"type":182,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100550799","phase-1-phase-1b-study-of-verve-201-in-patients-with-refractory-hyperlipidemia-100550799",false,"NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia","A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia","Inclusion Criteria:\n\n* Refractory hypercholesterolemia\n* Refractory hypertriglyceridemia\n\nExclusion Criteria:\n\n* Active or history of chronic liver disease\n* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":194,"type":195},36,"ESTIMATED","INTERVENTIONAL",[198],"PHASE1","VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.\n\nVERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.",[201,202,203],"Hypercholesterolemia","Hypertriglyceridemia","Refractory Hyperlipidemia",[32,205,206,207,208,209,210,203,211],"Gene Editing","Base Editing","Refractory Hypercholesterolemia","ANGPTL3","ASCVD","Refractory Hypertriglyceridemia","Familial Hypercholesterolemia","2026-07-15",{"date":214,"type":215},"2026-07-17","ACTUAL",{"date":217,"type":215},"2024-10-30",{"date":219,"type":195},"2027-12",{"name":5,"class":6},16]